StockNews.com initiated coverage on shares of Veradigm (NASDAQ:MDRX - Free Report) in a report released on Wednesday morning. The brokerage issued a hold rating on the software maker's stock.
Veradigm Stock Up 0.2 %
Shares of MDRX stock traded up $0.02 during trading hours on Wednesday, reaching $9.25. 195,735 shares of the stock traded hands, compared to its average volume of 1,727,018. The business has a fifty day moving average price of $9.59 and a 200 day moving average price of $9.06. Veradigm has a 1-year low of $5.01 and a 1-year high of $13.69.
Hedge Funds Weigh In On Veradigm
A number of large investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its position in Veradigm by 117.8% during the fourth quarter. Wellington Management Group LLP now owns 5,806,297 shares of the software maker's stock worth $60,908,000 after purchasing an additional 3,140,483 shares during the period. Tyro Capital Management LLC acquired a new stake in shares of Veradigm in the first quarter worth $9,055,000. Goldman Sachs Group Inc. boosted its holdings in shares of Veradigm by 6.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,596,684 shares of the software maker's stock worth $16,749,000 after buying an additional 99,528 shares during the period. Vanguard Group Inc. grew its stake in Veradigm by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 14,275,875 shares of the software maker's stock valued at $149,754,000 after buying an additional 95,291 shares during the last quarter. Finally, Meadow Creek Wealth Advisors LLC bought a new position in Veradigm in the 1st quarter worth $83,000.
Veradigm Company Profile
(
Get Free Report)
Veradigm Inc, a healthcare technology company, provides information technology solutions and services to healthcare organizations in the United States, Canada, and internationally. It offers electronic health records (EHR), information connectivity, private cloud hosting, outsourcing, analytics, patient access, and population health management solutions.
Further Reading
Before you consider Veradigm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Veradigm wasn't on the list.
While Veradigm currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
